IVIG-mediated effector functions in autoimmune and inflammatory diseases

Caroline Galeotti; Srini V Kaveri; Jagadeesh Bayry

doi:10.1093/intimm/dxx039

IVIG-mediated effector functions in autoimmune and inflammatory diseases

Int Immunol. 2017 Dec 30;29(11):491-498. doi: 10.1093/intimm/dxx039.

Authors

Caroline Galeotti^{1

2

3

4}, Srini V Kaveri^{1

2

3

5}, Jagadeesh Bayry^{1

2

3

5}

Affiliations

¹ Institut National de la Santé et de la Recherche Médicale Unité, France.
² Sorbonne Universités, UPMC Univ Paris 06, Paris, France.
³ Centre de Recherche des Cordeliers, Equipe -Immunopathologie et Immunointervention Thérapeutique, Paris, France.
⁴ Department of Pediatric Rheumatology, National Referral Centre of Auto-inflammatory Diseases, CHU de Bicêtre, France.
⁵ Université Paris Descartes, Sorbonne Paris Cité, France.

PMID: 28666326
DOI: 10.1093/intimm/dxx039

Abstract

Intravenous immunoglobulin (IVIG) is a pooled preparation of normal IgG obtained from several thousand healthy donors. It is widely used in the immunotherapy of a large number of autoimmune and inflammatory diseases. The mechanisms of action of IVIG are complex and, as discussed in this review, experimental and clinical data provide an indicator that the therapeutic benefit of IVIG therapy is due to several mutually non-exclusive mechanisms affecting soluble mediators as well as cellular components of the immune system. These mechanisms depend on Fc and/or F(ab')2 fragments. A better understanding of the effector functions of IVIG should help in identification of biomarkers of responses to IVIG in autoimmune patients.

Keywords: B cell; autoimmunity; dendritic cell; granulocyte; sialylation.

Publication types

Research Support, Non-U.S. Gov't
Review

MeSH terms

Autoimmune Diseases / immunology*
Autoimmune Diseases / therapy*
Humans
Immunoglobulins, Intravenous / immunology*
Immunoglobulins, Intravenous / therapeutic use*
Inflammation / immunology*
Inflammation / therapy*

Substances

Immunoglobulins, Intravenous